Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.05% | 6.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.05% | 6.45% | |||
| Cost of Revenue | 8.92% | -14.97% | |||
| Gross Profit | -21.01% | 70.74% | |||
| SG&A Expenses | -19.67% | 8.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.39% | -4.48% | |||
| Operating Income | 18.84% | 20.41% | |||
| Income Before Tax | 15.90% | 17.54% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | 15.90% | 18.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.90% | 18.11% | |||
| EBIT | 18.84% | 20.41% | |||
| EBITDA | 25.20% | 19.21% | |||
| EPS Basic | 15.38% | 18.75% | |||
| Normalized Basic EPS | 12.50% | 20.00% | |||
| EPS Diluted | 15.38% | 18.75% | |||
| Normalized Diluted EPS | 12.50% | 20.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||